De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx

Part of paid clinical trials in Orange, California.

Sponsor
University of California, Irvine
Study ID
NCT05600842
Status
Recruiting
Apply to this trial

Conditions

  • HPV Positive Oropharyngeal Squamous Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Intensity-Modulated Radiation Therapy (IMRT) — RADIATION
    IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.

Study Details

This is a single-arm, observational registry study determining the effects of reduced radiation dose in select patients with human papillomavirus (HPV) positive oropharyngeal cancer.

Key Dates

Start date
Nov 3, 2022
Status verified
Mar 2026
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
111 participants (estimated)

Arms

  • Arm: De-escalated radiotherapy

Primary Outcome Measure

2-Year Progression-Free Survival [ Time Frame: Given the natural history of this disease, PFS will be monitored up to 2 years from registration ]

Central Contacts

  • Chao Family Comprehensive Cancer Center University of California, Irvine
    877-827-8839
    [email protected]
  • University of California Irvine Medical

Locations (1)

FacilityCityStateZIPSite coordinators
Chao Family Comprehensive Cancer Center, University of California, IrvineOrangeCalifornia92868
Eric Chen, MD
[email protected]
877-827-8839

Find similar trials in Orange, CA

By research site
Chao Family Comprehensive Cancer Center, University of California, Irvine· Orange, CA

Related Studies